Levemir and Concomitant disease progression - a phase IV clinical study of FDA data

Summary:

Concomitant disease progression is reported as a side effect among people who take Levemir (insulin detemir recombinant), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Crestor, and have High blood pressure.

The phase IV clinical study analyzes which people have Concomitant disease progression when taking Levemir. It is created by eHealthMe based on reports of 13,520 people who have side effects when taking Levemir from the FDA, and is updated regularly.

What is Levemir?

Levemir has active ingredients of insulin detemir recombinant. It is often used in diabetes. eHealthMe is studying from 13,850 Levemir users. Check the latest studies of Levemir.

What is Concomitant disease progression?

Concomitant disease progression (progress in accompanying disease) is found to be associated with 372 drugs and 622 conditions by eHealthMe. Check the latest studies of Concomitant disease progression.

On Jul, 08, 2026

13,520 people reported to have side effects when taking Levemir.
Among them, 17 people (0.13%) have Concomitant disease progression.

Could Levemir cause Concomitant disease progression?

Among these 17 people:

How long have people been on Levemir when they have Concomitant disease progression? *

What is the gender of people who have Concomitant disease progression when taking Levemir? *

female: 11.76 %
male: 88.24 %

What is the age of people who have Concomitant disease progression when taking Levemir? *

What are other drugs people take besides Levemir? *

What are other side effects people have besides Concomitant disease progression? *

Hypovolaemia (a decreased volume of circulating blood in the body): 12 people, 70.59%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 12 people, 70.59%
Orthostatic Hypotension (a medical condition consisting of a sudden decrease in blood pressure when a person stands up): 12 people, 70.59%
Dizziness: 12 people, 70.59%
Haemothorax (collection of blood in the pleural space (the space between the lungs and the walls of the chest)): 7 people, 41.18%
Ventricular Fibrillation (abnormally irregular heart rhythm): 5 people, 29.41%
Cardiogenic Shock (inadequate circulation of blood): 5 people, 29.41%
Pneumonia: 4 people, 23.53%
Diabetic Foot Infection: 3 people, 17.65%
Bone Pain: 2 people, 11.76%

What are the existing conditions these people have? *

High Blood Pressure: 15 people, 88.24%
Insomnia (sleeplessness): 12 people, 70.59%
Hyperlipidaemia (presence of excess lipids in the blood): 12 people, 70.59%
Enlarged Prostate: 12 people, 70.59%
Cough: 12 people, 70.59%
Cardiac Failure Congestive: 12 people, 70.59%
Cardiac Failure Chronic: 12 people, 70.59%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 5 people, 29.41%
High Blood Cholesterol: 3 people, 17.65%
Diabetic Neuropathy (neuropathic disorders that are associated with diabetes mellitus): 3 people, 17.65%

* Approximation only. Some reports may have incomplete information.

Do you take Levemir and have Concomitant disease progression?

- Check whether Concomitant disease progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Levemir:

Levemir (13,850 reports)

Browse all side effects of Levemir:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Concomitant disease progression:

Concomitant disease progression (372 drugs)

Browse all the conditions that are associated with Concomitant disease progression:

Concomitant disease progression (622 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on insulin detemir recombinant (the active ingredients of Levemir) and Levemir (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.